Global Crohn's Disease Diagnostic and Therapeutic Market - Segmented by Type of Disease, Diagnosis, Treatment, and Geography - Growth, Trends, and Forecast (2022 - 2030)
The global Crohn's disease diagnostic and therapeutic market is estimated to grow at a good CAGR during the forecast period. Crohn’s disease (CD) is an inflammatory bowel disease (IBD) that can affect any part of the gastrointestinal tract from mouth to the anus. It is caused by a combination of environmental, immune, and bacterial factors, in genetically predisposed individuals.
Affected Population Increasing with Time
It is estimated that around 1.6 million Americans have the inflammatory bowel disease (IBD). This number includes about 780,000 population are having Crohn’s disease, and another 907,000 people are with ulcerative colitis. Research suggests that about six to 15 new cases of Crohn's disease are diagnosed per 100,000 people each year. People are most frequently diagnosed with Crohn's disease and ulcerative colitis in the late adolescence or in early adulthood, even though the diagnosis may happen at any age. Many population-based research studies have shown that Crohn's disease is somewhat more common in women than men, while ulcerative colitis is slightly more common in men than women. As the prevalence of the disease increases, it is expected to drive the Crohn's disease diagnostic and therapeutic market.
Also, the increasing demand for prompt diagnosis and multiple symptoms associated with the disease requiring individual therapeutic attention, are increasing the growth of the market.
Lack of a Cost-effective Treatment
Current costs for the treatment and diagnosis of Crohn's disease is high, due to the availability of several new therapeutic drugs and changes in the surgical treatment of the disease. For example, the total cost of Crohn's disease in the United States is around USD 3.6 billion every year, and the average yearly medical cost per patient is about USD 8,265, with more than one-third of that cost being medications. Biologic medications or drugs are usually expensive. Hospitalization accounted for 31.4% of the cost. On an average, people who have to be hospitalized for Crohn’s disease are expected to spend about 5.8 days in the hospital. All these treatment cost issues are hindering the Crohn's diagnostic and therapeutic market. Also, as no specific treatment or drug is available in the market, and there is lack of awareness among the people coupled with symptom similarity with other gastrointestinal disease are hindering the market growth.
North America to Lead the Market
North America is dominating the Crohn's disease diagnostic and therapeutic market due to the increasing prevalence of Crohn's disease in the region. Asia-Pacific is expected to record a substantial growth in the forecast period.
Key Developments in the Market
• February 2018: AbbVie announced New Phase II data for Upadacitinib showing the clinical and endoscopic outcomes in Crohn's disease at 52 weeks.
Major Players: ABBVIE, CELGENE CORPORATION, GENENTECH, JANSSEN BIOTECH INC., PFIZER INC., PROMETHEUS LABORATORIES, INC. (NESTLE), SALIX PHARMACEUTICALS, INC. (VALEANT PHARMACEUTICALS), TAKEDA'S PHARMACEUTICAL LTD, and JOHNSON & JOHNSON, among others.
Reasons to Purchase the Report
• Follow the current and future global Crohn's disease diagnostic and therapeutic market in the developed and emerging markets.
• Analyzing various perspectives of the market with the help of Porter’s
• Five Forces Analysis.
• Identify the segment that is expected to dominate the market.
• Identify the regions that are expected to witness the fastest growth during the forecast period.
• Identify the latest developments, market shares, and strategies employed by the major market players.
• 3-month analyst support along with the Market Estimate sheet (in Excel).
Customization of the Report
This report can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Affected Population Increasing with Time
It is estimated that around 1.6 million Americans have the inflammatory bowel disease (IBD). This number includes about 780,000 population are having Crohn’s disease, and another 907,000 people are with ulcerative colitis. Research suggests that about six to 15 new cases of Crohn's disease are diagnosed per 100,000 people each year. People are most frequently diagnosed with Crohn's disease and ulcerative colitis in the late adolescence or in early adulthood, even though the diagnosis may happen at any age. Many population-based research studies have shown that Crohn's disease is somewhat more common in women than men, while ulcerative colitis is slightly more common in men than women. As the prevalence of the disease increases, it is expected to drive the Crohn's disease diagnostic and therapeutic market.
Also, the increasing demand for prompt diagnosis and multiple symptoms associated with the disease requiring individual therapeutic attention, are increasing the growth of the market.
Lack of a Cost-effective Treatment
Current costs for the treatment and diagnosis of Crohn's disease is high, due to the availability of several new therapeutic drugs and changes in the surgical treatment of the disease. For example, the total cost of Crohn's disease in the United States is around USD 3.6 billion every year, and the average yearly medical cost per patient is about USD 8,265, with more than one-third of that cost being medications. Biologic medications or drugs are usually expensive. Hospitalization accounted for 31.4% of the cost. On an average, people who have to be hospitalized for Crohn’s disease are expected to spend about 5.8 days in the hospital. All these treatment cost issues are hindering the Crohn's diagnostic and therapeutic market. Also, as no specific treatment or drug is available in the market, and there is lack of awareness among the people coupled with symptom similarity with other gastrointestinal disease are hindering the market growth.
North America to Lead the Market
North America is dominating the Crohn's disease diagnostic and therapeutic market due to the increasing prevalence of Crohn's disease in the region. Asia-Pacific is expected to record a substantial growth in the forecast period.
Key Developments in the Market
• February 2018: AbbVie announced New Phase II data for Upadacitinib showing the clinical and endoscopic outcomes in Crohn's disease at 52 weeks.
Major Players: ABBVIE, CELGENE CORPORATION, GENENTECH, JANSSEN BIOTECH INC., PFIZER INC., PROMETHEUS LABORATORIES, INC. (NESTLE), SALIX PHARMACEUTICALS, INC. (VALEANT PHARMACEUTICALS), TAKEDA'S PHARMACEUTICAL LTD, and JOHNSON & JOHNSON, among others.
Reasons to Purchase the Report
• Follow the current and future global Crohn's disease diagnostic and therapeutic market in the developed and emerging markets.
• Analyzing various perspectives of the market with the help of Porter’s
• Five Forces Analysis.
• Identify the segment that is expected to dominate the market.
• Identify the regions that are expected to witness the fastest growth during the forecast period.
• Identify the latest developments, market shares, and strategies employed by the major market players.
• 3-month analyst support along with the Market Estimate sheet (in Excel).
Customization of the Report
This report can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Please Select a Format
